Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Liabilities: 2014-2024

Historic Total Liabilities for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $441.8 million.

  • Cartesian Therapeutics' Total Liabilities fell 10.13% to $408.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $408.5 million, marking a year-over-year decrease of 10.13%. This contributed to the annual value of $441.8 million for FY2024, which is 0.64% down from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Total Liabilities is $441.8 million, which was down 0.64% from $444.7 million recorded in FY2023.
  • Cartesian Therapeutics' Total Liabilities' 5-year high stood at $444.7 million during FY2023, with a 5-year trough of $72.1 million in FY2022.
  • Its 3-year average for Total Liabilities is $319.5 million, with a median of $441.8 million in 2024.
  • In the last 5 years, Cartesian Therapeutics' Total Liabilities slumped by 47.54% in 2022 and then spiked by 517.11% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Total Liabilities (Yearly) stood at $183.4 million in 2020, then declined by 25.12% to $137.4 million in 2021, then plummeted by 47.54% to $72.1 million in 2022, then surged by 517.11% to $444.7 million in 2023, then declined by 0.64% to $441.8 million in 2024.